Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
- PMID: 17637754
- PMCID: PMC2646890
- DOI: 10.1038/sj.onc.1210640
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
Abstract
New predictive markers for managing prostate cancer are urgently required because of the highly variable natural history of this disease. At the time of diagnosis, Gleason score provides the gold standard for assessing the aggressiveness of prostate cancer. However, the recent discovery of TMPRSS2 fusions to the ERG gene in prostate cancer raises the possibility of using alterations at the ERG locus as additional mechanism-based prognostic indicators. Fluorescence in situ hybridization (FISH) assays were used to assess ERG gene status in a cohort of 445 prostate cancers from patients who had been conservatively managed. The FISH assays detected separation of 5' (labelled green) and 3' (labelled red) ERG sequences, which is a consequence of the TMPRSS2-ERG fusion, and additionally identify interstitial deletion of genomic sequences between the tandemly located TMPRSS2 and ERG gene sequences on chromosome 21. Cancers lacking ERG alterations exhibited favourable cause-specific survival (90% survival at 8 years). We identify a novel category of prostate cancers, characterized by duplication of the fusion of TMPRSS2 to ERG sequences together with interstitial deletion of sequences 5' to ERG (called '2+Edel'), which by comparison exhibited extremely poor cause-specific survival (hazard ratio=6.10, 95% confidence ratio=3.33-11.15, P<0.001, 25% survival at 8 years). In multivariate analysis, '2+Edel' provided significant prognostic information (P=0.003) in addition to that provided by Gleason score and prostate-specific antigen level at diagnosis. Other individual categories of ERG alteration were associated with intermediate or good prognosis. We conclude that determination of ERG gene status, including duplication of the fusion of TMPRSS2 to ERG sequences in 2+Edel, allows stratification of prostate cancer into distinct survival categories.
Figures






Similar articles
-
TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.Mod Pathol. 2009 Nov;22(11):1415-22. doi: 10.1038/modpathol.2009.121. Epub 2009 Sep 4. Mod Pathol. 2009. PMID: 19734849 Free PMC article.
-
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.Cancer Res. 2006 Nov 15;66(22):10658-63. doi: 10.1158/0008-5472.CAN-06-1871. Cancer Res. 2006. PMID: 17108102
-
Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.Mod Pathol. 2007 Sep;20(9):921-8. doi: 10.1038/modpathol.3800903. Epub 2007 Jul 13. Mod Pathol. 2007. PMID: 17632455
-
The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.Dan Med J. 2016 Dec;63(12):B5319. Dan Med J. 2016. PMID: 27910803 Review.
-
Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review.Asian J Androl. 2020 Mar-Apr;22(2):200-207. doi: 10.4103/aja.aja_45_19. Asian J Androl. 2020. PMID: 31210145 Free PMC article.
Cited by
-
Recurrent rearrangements in prostate cancer: causes and therapeutic potential.Curr Drug Targets. 2013 Apr;14(4):450-9. doi: 10.2174/1389450111314040006. Curr Drug Targets. 2013. PMID: 23410129 Free PMC article. Review.
-
Assays for prostate cancer : changing the screening paradigm?Mol Diagn Ther. 2013 Feb;17(1):1-8. doi: 10.1007/s40291-013-0014-y. Mol Diagn Ther. 2013. PMID: 23355098
-
Preliminary Results of Noninvasive Detection of TMPRSS2:ERG Gene Fusion in a Cohort of Patients With Localized Prostate Cancer.Korean J Urol. 2013 Jun;54(6):359-63. doi: 10.4111/kju.2013.54.6.359. Epub 2013 Jun 12. Korean J Urol. 2013. PMID: 23789042 Free PMC article.
-
TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.Hum Pathol. 2011 Jan;42(1):11-7. doi: 10.1016/j.humpath.2010.05.026. Epub 2010 Oct 30. Hum Pathol. 2011. PMID: 21040948 Free PMC article.
-
An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy.Intern Med. 2020 Feb 1;59(3):395-399. doi: 10.2169/internalmedicine.3302-19. Epub 2019 Oct 17. Intern Med. 2020. PMID: 31619598 Free PMC article.
References
-
- Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of clinically localized low-grade prostate cancer: actual 10 year and projected 15 year follow up of the karolinska series. Urology. 1997;50:722–726. - PubMed
-
- Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626–631. - PubMed
-
- Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowakczyk PD, Sanders MM, et al. Cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97:1248–1253. - PubMed
-
- Allsbrook WC, Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, et al. Interobserver reproducibility of gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol. 2001a;32:74–80. - PubMed
-
- Allsbrook WC, Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of gleason grading of prostatic carcinoma: general pathologist. Hum Pathol. 2001b;32:81–88. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical